PVLA: NDA for QTORIN rapamycin submitted; commercial launch and pipeline expansion expected next year
Focused on first-in-disease therapies for rare skin and vascular diseases, the company has submitted an NDA for QTORIN rapamycin and is advancing multiple clinical programs with strong FDA support. Launch planning is robust, backed by significant funding and a seasoned team.Based on Palvella Therap…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.